![Martin Duvall](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Duvall
Président chez
Oncopeptides, Inc.
Profil
Martin J.
Duvall is currently the Chairman of Oncopeptides, Inc. and a Director of Oncopeptides Incentive AB. He was previously the Chief Executive Officer & Director of Tocagen, Inc. and the Chief Executive Officer of Oncopeptides AB. He has also held senior positions at Merck & Co., Inc., MGI PHARMA, Inc., ARIAD Pharmaceuticals, Inc., and Abraxis BioScience, Inc. He was a Vice President at Aventis Pharmaceuticals, Inc. Mr. Duvall has a graduate degree from The Johns Hopkins University, an undergraduate degree from Muhlenberg College, and an MBA from the University of Kansas.
Postes actifs de Martin Duvall
| Sociétés | Poste | Début |
|---|---|---|
MGI PHARMA Biologics, Inc.
 MGI PHARMA Biologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical and medical therapies | Corporate Officer/Principal | 01/11/2004 |
Oncopeptides, Inc.
 Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Develops therapies for hematological diseases | Président | - |
Oncopeptides Incentive AB | Directeur/Membre du Conseil | - |
Anciens postes connus de Martin Duvall
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOPEPTIDES AB | Directeur Général | 15/11/2021 |
| FORTE BIOSCIENCES, INC. | Directeur Général | 15/06/2020 |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 26/05/2016 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/09/2011 |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Corporate Officer/Principal | 27/04/2011 |
Formation de Martin Duvall
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
69
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Health Technology |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Develops biopharmaceutical drugs | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Muhlenberg College
 Muhlenberg College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
MGI PHARMA Biologics, Inc.
MGI PHARMA Biologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical and medical therapies | Health Technology |
Oncopeptides Incentive AB | |
Oncopeptides, Inc.
Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Develops therapies for hematological diseases | Health Services |
